• B. Socea 1Clinical Emergency Hospital “Sf. Pantelimon”, Bucharest, Romania 2The University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
  • Roxana Turturea 3County Clinical Hospital, Cluj-Napoca, Romania
  • Andra Morar 4Clinical Hospital of Infectious Diseases, Cluj-Napoca, Romania
  • Cristina Moldovan 3County Clinical Hospital, Cluj-Napoca, Romania
  • Alexandra Bolocan 2The University of Medicine and Pharmacy Carol Davila, Bucharest, Romania 5Emergency University Hospital of Bucharest, Romania
  • Oana Botezan 3County Clinical Hospital, Cluj-Napoca, Romania
  • Alexandra Ene 3County Clinical Hospital, Cluj-Napoca, Romania
  • Mara Carsote „C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania & „Carol Davila” University of Medicine and Pharmacy of Bucharest, Romania
  • Ana Valea 3County Clinical Hospital, Cluj-Napoca, Romania 7I. Hatieganu University of Medicine and Pharmacy, Romania
Keywords: macroadenoma, pituitary, hypopituitarism


Hypopituitarism is the main complication of nonfunctioning  pituitary macroadenomas. A 64-year-old patient was admitted for marked asthenia, generalized muscle contractions, acroparesthesia and lumbar pain. Clinical examination revealed grade I obesity, discrete eyelid edema, negative Chwosteckand Trousseau signs. Hormonal profile showed the presence of somathotropic pituitary insufficiency, low testosterone levels (of 1.3 ng/mL, normal: 1.68-7.58ng/mL), gonadotropin and prolactin levels within the normal range, normal values for TSH (Thyroid Stimulated Hormone) and FT4 (Free Thyroxine).  On admission, low serum and urinary cortisol values were obtained, with an appropriate response after the Synacthen test. The MRI (Magnetic Resonance Investigation) examination revealed a pituitary macroadenoma of 20/21/21 mm, compressing the optic chiasm and thalamus, with bilateral 180-degree involvement of the internal carotid artery. The ophthalmological examination described a lower scotoma in the left eye, without amputation of the visual field. Thyroid and glucocorticoid hormone replacement therapy was recommended, along with neurosurgical intervention. In pituitary macroadenomas, the close proximity to the optic chiasm and carotid arteries limits the curative therapeutic potential and increases the risk of postoperative complications.


[1]The pituitary society. Viewed April 27, 2015.
[2]M.H. Murad,M.M. Fernández-Balsells, A. Barwise, J.F. Gallegos-Orozco, A. Paul, M.A. Lane, et al. Outcomes of surgical treatment for nonfunctioning pituitary adenomas: a systematic review and meta-analysis, ClinEndicrinol (Oxf) 2010;73:777–91.
[3]S. Saunders, J.P. Vora. Endocrine evaluation of pituitary tumours, Br J Neurosurg 2008;22(4):602–8.
[4]Y. Chen, C.D. Wang, Z.P. Su, Y.X. Chen, L. Cai, Q.C. Zhuge, Z.B. Wu. Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis, Neuroendocrinology 2012;96:333–42.
[5]C.A. Jaffe. Clinically non-functioning pituitary adenoma, Pituitary 2006;9:317–21.
[6]O.M. Dekkers, A.M. Pereira, J.A. Romijn. Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas, J ClinEndocrinolMetab 2008;93(10):3717–26.
[7]D. Zhao, Y. Tomono, K. Tsuboi, T. Nose. Immunohistochemical and ultrastructural study of clinically nonfunctioning pituitary adenomas, Neurol Med Chir (Tokyo) 2000: 40453-456.
[8]R.Loch Batista, E. Barbosa Trarbach, M. Diniz Marques, V. Angelo Cescato, G. Ochmanda Silva, G. Clarissa,et al. Nonfunctioning Pituitary Adenoma Recurrence and Its Relationship with Sex, Size, and Hormonal Immunohistochemical Profile, World Neurosurgery 2018: e241-e246.
[9]S. Yamada, K. Ohyama, M. Taguchi, A. Takeshita, K. Morita, K. Takano, T. Sano. A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas, Neurosurgery 2007;61:580 –584.
[10]J.J. Kanski. Clinical Ophthalmology 6thed. London, UK: Butterworth Heinemann, 2007: 811.
[11]B.M. Arafah, M.P. Nasrallah. Pituitary tumors: pathophysiology, clinical manifestations and management, EndocrRel Cancer 200; 8: 287–305.
[12]D.J. Baruffi,K.R. Thompson. Radiologic presentation of pituitary adenoma, Optom Vis Sci 2012; 89: e56–e64.
[13]G.S. Kosmorsky, W.J. Dupps, R.L. Drake. Non‐uniform pressure generation in the optic chiasm may explain bitemporalhemianopsia, Ophthalmology 2008; 115: 560–565.
[14]A. Prete, M.C. Salvatore, R. Salvatori, Current best practice in the management of patients after pituitary surgery, TherAdvEndocrinolMetab 2017 Mar; 8(3): 33–48.
[15]Poiana C, Chirita C, Carsote M, Hortopan D, Goldstein A. Galactocele and prolactinoma--a pathogenic association?Maturitas. 2009 Jan 20;62(1):98-102. doi: 10.1016/j.maturitas.2008.10.015. Epub 2008 Dec 24.
[16]Dumitru N, Ghemigian A, Carsote M, Albu SE, Terzea D, Valea A. Thyroid nodules after initial evaluation by primary health care practitioners: an ultrasound pictorial essay. Archives of the Balkan Medical Union 2016; 51 (3), 434-438
[17]R.F. Dallapiazza , J.A. Jane Jr. Outcomes of endoscopic transsphenoidal pituitary surgery. Endocrinol Metab Clin North Am. 2015 Mar;44(1):105-15.
[18]M.K. Jang , C.G. Park , S. Jang , E.H. Kim . Prevalence and Impact of Postoperative Headaches in Nonfunctioning Pituitary Macroadenoma Patients: A Longitudinal Cohort Study. World Neurosurg. 2019 Oct 8. pii: S1878-8750(19)32565-3. doi: 10.1016/j.wneu.2019.09.123.
[19]T. Ogiwara , A. Nagm , T. Nakamura , T. Mbadugha , T. Horiuchi , K. Hongo . Significance and Indications of Surgery for Asymptomatic Nonfunctioning Pituitary Adenomas. World Neurosurg. 2019 May 8. pii: S1878-8750(19)31257-4. doi: 10.1016/j.wneu.2019.04.250.
[20] M. Harary , A.C. DiRisio , H.Y. Dawood , J. Kim, N. Lamba , C.H. Cho , T.R. Smith , H.A. Zaidi, E.R. Laws . Endocrine function and gland volume after endoscopic transsphenoidal surgery for nonfunctional pituitary macroadenomas. J Neurosurg. 2018 Nov 1:1-10. doi: 10.3171/2018.5.JNS181054.
[21]Valea A, Ghervan C, Carsote M, Morar A, Iacob I, Tomesc F, Pop DD, Georgescu C. Effects of combination therapy: somatostatin analogues and dopamine agonists on GH and IGF1 levels in acromegaly. Clujul Med. 2015;88(3):310-3. doi: 10.15386/cjmed-435.
[22]M.E Molitch. . Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017 Feb 7;317(5):516-524. doi: 10.1001/jama.2016.19699.
[23]G. Iván , N. Szigeti-Csúcs , M. Oláh , G.M. Nagy , M.I. Góth . Treatment of pituitary tumors: dopamine agonists. Endocrine. 2005 Oct;28(1):101-10
[24]E. Kuhn , P. Chanson . Cabergoline in acromegaly. Pituitary. 2017 Feb;20(1):121-128. doi: 10.1007/s11102-016-0782-6.
[25]R.S. Auriemma , R. Pivonello , L. Ferreri ,P. Priscitelli , A. Colao . Cabergoline use for pituitary tumors and valvular disorders. Endocrinol Metab Clin North Am. 2015 Mar;44(1):89-97. doi: 10.1016/j.ecl.2014.10.007.
[26]R. Palui , J. Sahoo , S. Kamalanathan, S.S. Kar , S. Selvarajan , H. Durgia . Effect of cabergoline monotherapy in Cushing's disease: an individual participant data meta-analysis. J Endocrinol Invest. 2018 Dec;41(12):1445-1455. doi: 10.1007/s40618-018-0936-7.
How to Cite